165 related articles for article (PubMed ID: 37597214)
1. Lymph node ratio is a prognostic indicator for locally advanced esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy.
Chen P; Wang L; Yang X; Feng J
Biomol Biomed; 2024 Jan; 24(1):159-169. PubMed ID: 37597214
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological Significance of Pathologic Complete Lymph Node Regression After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma.
Hsu PK; Yeh YC; Chien LI; Huang CS; Hsu HS
Ann Surg Oncol; 2021 Apr; 28(4):2048-2058. PubMed ID: 33216266
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment Pan-Immune-Inflammation Value (PIV) in Predicting Therapeutic Response and Clinical Outcomes of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Ann Surg Oncol; 2024 Jan; 31(1):272-283. PubMed ID: 37838648
[TBL] [Abstract][Full Text] [Related]
4. The Prognostic Value of Lymph Node Ratio in Locally Advanced Esophageal Cancer Patients Who Received Neoadjuvant Chemotherapy.
Kano K; Yamada T; Komori K; Watanabe H; Takahashi K; Fujikawa H; Numata M; Aoyama T; Tamagawa H; Yukawa N; Rino Y; Masuda M; Ogata T; Oshima T
Ann Surg Oncol; 2021 Dec; 28(13):8464-8472. PubMed ID: 34114182
[TBL] [Abstract][Full Text] [Related]
5. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
[TBL] [Abstract][Full Text] [Related]
6. The usefulness of pretreatment controlling nutritional status score for predicting recurrence in patients with esophageal squamous cell carcinoma undergoing neoadjuvant immunochemotherapy: A real-world study.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Front Immunol; 2022; 13():1015365. PubMed ID: 36505443
[TBL] [Abstract][Full Text] [Related]
7. A novel immune-nutritional score predicts response to neoadjuvant immunochemotherapy after minimally invasive esophagectomy for esophageal squamous cell carcinoma.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Front Immunol; 2023; 14():1217967. PubMed ID: 37954582
[TBL] [Abstract][Full Text] [Related]
8. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Tian Y; Shi Z; Wang C; Ke S; Qiu H; Zhao W; Wu Y; Chen J; Zhang Y; Chen Y
Ann Surg Oncol; 2024 Feb; 31(2):860-871. PubMed ID: 37947979
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy.
Agarwal R; Philip A; Pavithran K; Rajanbabu A; Goel G; Vijaykumar DK
Indian J Cancer; 2019; 56(3):228-235. PubMed ID: 31389386
[TBL] [Abstract][Full Text] [Related]
10. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.
Gao L; Hong ZN; Wu L; Yang Y; Kang M
Front Immunol; 2022; 13():1008681. PubMed ID: 36569913
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of geriatric nutritional risk index in esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Eur J Surg Oncol; 2024 Jun; 50(6):108323. PubMed ID: 38603867
[TBL] [Abstract][Full Text] [Related]
12. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.
Lv H; Zhang F; Huang C; Xu S; Li J; Sun B; Gai C; Liu Z; Wang M; Li Z; Tian Z
J Cancer Res Clin Oncol; 2024 May; 150(5):260. PubMed ID: 38760614
[TBL] [Abstract][Full Text] [Related]
13. Impact of postoperative lymph node status on the prognosis of esophageal squamous cell carcinoma after esophagectomy following neoadjuvant chemoradiotherapy: a retrospective study.
Sun Z; Xu X; Zhao X; Ma X; Ye Q
J Gastrointest Oncol; 2021 Dec; 12(6):2685-2695. PubMed ID: 35070398
[TBL] [Abstract][Full Text] [Related]
14. Impact of Lymph Node Ratio on Survival Outcome in Esophageal Squamous Cell Carcinoma After Minimally Invasive Esophagectomy.
Kitamura Y; Oshikiri T; Takiguchi G; Urakawa N; Hasegawa H; Yamamoto M; Kanaji S; Yamashita K; Matsuda T; Fujino Y; Tominaga M; Nakamura T; Suzuki S; Kakeji Y
Ann Surg Oncol; 2021 Aug; 28(8):4519-4528. PubMed ID: 33393049
[TBL] [Abstract][Full Text] [Related]
15. Lymph node ratio-based staging system for esophageal squamous cell carcinoma.
Chen SB; Weng HR; Wang G; Zou XF; Liu DT; Chen YP; Zhang H
World J Gastroenterol; 2015 Jun; 21(24):7514-21. PubMed ID: 26139998
[TBL] [Abstract][Full Text] [Related]
16. Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
Hong ZN; Huang Z; Weng K; Lin J; Kang M
Front Immunol; 2022; 13():1036396. PubMed ID: 36311738
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
Leng X; He W; Yang H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Liu H; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Fu J; Han Y
Ann Surg; 2021 Dec; 274(6):e1022-e1029. PubMed ID: 31855875
[TBL] [Abstract][Full Text] [Related]
18. Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
Ruan Y; Ma Y; Ma M; Liu C; Su D; Guan X; Yang R; Wang H; Li T; Zhou Y; Ma J; Zhang Y
J Transl Med; 2024 May; 22(1):471. PubMed ID: 38762454
[TBL] [Abstract][Full Text] [Related]
19. Lymph node ratio as best prognostic factor in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy.
De la Cruz-Ku GA; Chambergo-Michilot D; Valcarcel B; Rebaza P; Möller M; Araujo JM; Enriquez D; Morante Z; Razuri C; Luque R; Saavedra A; Eyzaguirre E; Lujan M; Noel N; Pinto J; Cotrina J; Gomez H
Breast J; 2020 Sep; 26(9):1659-1666. PubMed ID: 32713113
[TBL] [Abstract][Full Text] [Related]
20. Lymph Node Ratio Improves Prediction of Overall Survival in Esophageal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy: A National Cancer Database Analysis.
Zhang Y; Cao Y; Zhang J; Huang M; Roy P; Huang B; Yang H; Rong Y; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Lin J; Zhang J; Fu J; He J; Li H
Ann Surg; 2023 Jun; 277(6):e1239-e1246. PubMed ID: 35797545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
